TO PA-99-124

Release Date:  November 10, 1999

NOTICE:  AI-00-001

National Institute of Allergy and Infectious Disease

Application Receipt Dates:  January 2, May 1, September 1

This notice is an addendum to expand the research objectives that are 
responsive to PA-99-124, "Therapeutics Research on AIDS-Associated 
Opportunistic Infections," which was published in the NIH Guide for 
Grants and Contracts, July 9, 1999.  This addendum also includes an 
addition to mechanism of support, and an addition to other interested 
institutes within NIH.


The following is added:

The number of R03 amended applications is limited to one.


The following opportunistic pathogen is added:

Pneumocystis carinii pneumonia (PCP) remains a major cause of morbidity 
and mortality in HIV-infected persons despite the use of the available 
prophylactic agents and more effective antiretroviral drugs. For 
individuals who cannot tolerate the preferred agent for prevention of 
PCP, trimethoprim-sulfamethoxazole (TMP/SMZ), alternative regimens are 
available and include aerosolized pentamidine, dapsone, and atovaquone.  
However, all these alternatives are significantly less effective than 
TMP/SMZ.  Should current antiretroviral therapy failures become more 
widespread, PCP could again emerge as a frequent life-threatening 
complication.  In addition, successful therapy may become more 
difficult to achieve if P. carinii strains resistant to sulfonamides 
and dapsone become progressively more common.   

Addition to INQUIRIES

The National Heart, Lung, and Blood Institute (NHLBI) has additional 
interest in supporting research on the pulmonary, cardiovascular and 
hematologic aspects of opportunistic infections associated with HIV 
infection.  The National Institute of Dental and Craniofacial Research 
(NIDCR) has additional interest in opportunistic infections in the oral 

The following Institute is added as a sponsor of this PA:

The National Institute of Diabetes and Digestive and Kidney Diseases 
(NIDDK) has an interest in supporting research on the influence of 
opportunistic pathogens on the enterocytes in the gastrointestinal 
tract as well as the hepatocytes in the liver in disease expression.  
Therefore, applications of mutual interest are likely to be given a 
secondary assignment to NIDDK in accordance with the NIH referral 
guidelines.  Inquiries regarding NIDDK programmatic issues may be 
directed to:

Frank A. Hamilton, M.D., MPH
Chief, Digestive Diseases Program Branch
Natcher Building 45, Room 6AN12B
National Institutes of Health
45 Center Drive  MSC 6600
Bethesda, MD  20892
Telephone:	301-594-8877
FAX:		301-480-8300


Direct inquires regarding programmatic issues to:

Chris Lambros, Ph.D.
Division of AIDS
Room 5227
6700-B Rockledge Drive, MSC 7624
Bethesda, MD  20892-7624
Telephone:	301-435-3769
FAX:		301-402-3171

Direct inquiries regarding fiscal and administrative matters to:

Ms. Linda M. Shaw
Division of Extramural Activities
Room 2125
6700-B Rockledge Drive, MSC 7614
Bethesda, MD  20892-7614
Telephone:	301-402-6611
FAX:		301-480-3780

Return to Volume Index

Return to NIH Guide Main Index

Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS) - Government Made Easy

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.